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hiazolidinediones (TZD) have a variety of car-
diovascular effects (1), and despite the expectation
of cardiovascular benefits from improved glyce-
mic control, some members of the group appear
o have an adverse effect on mortality (2). These para-
oxical findings reflect the complexities of the patho-
hysiological processes linking diabetes to adverse car-
iovascular outcomes, including effects on atheroma
urden, plaque vulnerability (including necrosis and in-
ammation), and platelet activity. In this issue of
JACC, 2 papers use imaging techniques to address
he role of TZDs in plaque inflammation in animals
nd humans (3,4). Both studies show this agent to
educe plaque inflammation, as evidenced by fluoro-
eoxyglucose uptake relative to controls; 1 of the
anuscripts also showed histologically-verified re-
uction of neovascularization. These findings, which
uggest a role for pioglitazone in reducing plaque vul-
erability, supplement previous studies that demon-
trate reduced plaque burden with TZDs (5,6).
These studies provide mechanistic information
bout the effects of TZDs on the cardiovascular
ystem, but it would not be appropriate to con-
lude from these findings that the concern about
he cardiovascular sequelae of TZDs was ill-
laced or that we should feel reassured about the
ardiovascular safety of these agents. Despite
hese reassuring findings, we need to recognize
hat the effects of these agents are complex and
nconsistent (7,8), and more importantly, the lim-
tations of using surrogate endpoints and a re-
inder for us to focus on the “bigger picture” (9).
Nearly 20 years ago, the U.S. Food and Drug
dministration defined a surrogate endpoint as a
aboratory measurement that can be used as a sub-
From the *Cleveland Clinic, Cleveland, Ohio; and †Mount Sinai Hos-
pital, New York, New York.titute for a clinically meaningful endpoint (e.g.,
ealth status, functional status, or survival) and that
s expected to predict the effect of the therapy (10).
n situations where achievement of adequate statisti-
al power with clinical outcomes would require large
umbers of patients to be followed over long peri-
ds, their substitution with surrogates can control
he size, duration, and cost of studies. The Prentice
riteria (11) broadly stipulate that the marker (in
his case, plaque burden or inflammation) should be
ssociated with clinical outcome, but they also re-
uire that the marker fully capture the net effect of
reatment on outcome. Both components of this
efinition are potential sources of problems. For ex-
mple, while clinicians use blood pressure, glycosy-
ated hemoglobin, and intraocular pressure as valid
arkers of the risks of hypertensive complications,
iabetic microvascular complications, and visual loss
rom glaucoma, arrhythmia suppression is not a
ood surrogate for long-term survival (12). None-
heless, the greater barrier is posed by the second
omponent of these criteria. Perhaps the best exam-
le is that of torcetrapib, which documented a bene-
cial effect on high-density lipoprotein, but was as-
ociated with an increase in adverse cardiovascular
vents (13). Generally, the association of surrogate
ndpoints with outcome seems to be dependent on
he complexity of the process involved. The TZD
gents are involved in many pathways, such that a
avorable response in one part maybe counterbal-
nced by an unfavorable response in another.
Fleming and DeMets (14) described 4 path-
ays through which surrogates may fail as mark-
rs of hard endpoints, which may be applied to
he specific topic of TZD evaluation:
. Absence of the surrogate from the causal path-
way of disease. This might apply to studies
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1147where improved glycemic control is used as a
surrogate of macrovascular disease endpoints.
. Presence of multiple causal pathways. Several
studies have documented an association of
TZD with a reduction of atherosclerotic bur-
den, for example, based on reduced carotid
intima-medial thickness (3,4). There is a risk in
overstating the importance of this finding; few
patients die from increasing atherosclerotic bur-
den, in comparison with the numbers develop-
ing acute complications due to plaque rupture
and thrombosis. Indeed, while composite anal-
yses of studies linking the regression of coronary
plaque burden to reduced coronary events have
shown them to be associated (15), the clinical
outcome that dominates this link is revascular-
ization rather than mortality.
. Involvement of the surrogate in the pathway,Searching for the right outcome? A
1
1
clinical trials: defidrug, even if it is effective. This might apply to
other indexes of plaque instability, such as
necrosis and apoptosis (7).
. The effect of the drug has disease-independent
effects that may not influence the surrogate.
The TZDs have multiple pleiotropic effects,
including on hypertension, angiotensin-2,
and renal protection (16), that may benefit
outcome and yet not influence imaging sur-
rogates.
he limitation of imaging surrogates for agents such
s TZDs is that they influence a huge variety of
athways, extending even to associations with neopla-
ia (17). Imaging markers teach valuable lessons about
iological activity. They supplement but may not
ecessarily replace the need for clinical outcomes
tudies defining the long-term risks and benefits ofwithout the surrogate being influenced by the pharmacological interventions (18).1
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